These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16487834)

  • 21. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
    Young JJ
    J Invasive Cardiol; 2005 Jun; 17(6):300-1. PubMed ID: 16003003
    [No Abstract]   [Full Text] [Related]  

  • 23. Acute coronary syndrome: new advances and nursing strategies.
    Palatnik AM
    Dimens Crit Care Nurs; 2000; 19(5):22-6. PubMed ID: 11998062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delivery of glycoprotein IIb/IIIa inhibitor therapy for percutaneous coronary intervention: why not take the intracoronary highway?
    Gurbel PA; Tantry US
    Circulation; 2010 Feb; 121(6):739-41. PubMed ID: 20124130
    [No Abstract]   [Full Text] [Related]  

  • 25. Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial.
    Labinaz M; Kaul P; Harrington RA; Chang WC; Kleiman NS; Simoons ML; Boersma E; Akkerhuis KM; Califf RM; Armstrong PW;
    Can J Cardiol; 2004 Jun; 20(8):773-8. PubMed ID: 15229770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interventional therapy for coronary artery disease.
    Shah PB; Lilly CM
    Am J Respir Crit Care Med; 2002 Sep; 166(6):791-6. PubMed ID: 12231486
    [No Abstract]   [Full Text] [Related]  

  • 27. [Guidelines for percutaneous coronary interventions].
    Silber S; Albertsson P; Avilés FF; Camici PG; Colombo A; Hamm C; Jørgensen E; Marco J; Nordrehaug JE; Ruzyllo W; Urban P; Stone GW; Wijns W;
    Ital Heart J Suppl; 2005 Jul; 6(7):427-74. PubMed ID: 16082826
    [No Abstract]   [Full Text] [Related]  

  • 28. Post-procedural patient management: prevention and management of bleeding complications.
    Aguirre F
    J Invasive Cardiol; 1994; 6 Suppl A():34A-37A; discussion 54A-56A. PubMed ID: 10155093
    [No Abstract]   [Full Text] [Related]  

  • 29. The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention.
    Mayes CE; Kandzari DE; Goldschmidt-Clermont PJ; Phillips HR
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():36E-46E; quiz 47E. PubMed ID: 12668861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimization of platelet therapy.
    Fry JA; Grines CL
    Semin Interv Cardiol; 2000 Sep; 5(3):117-28. PubMed ID: 11054909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda.
    Leopold JA; Antman EM
    Circulation; 2005 Mar; 111(9):1097-9. PubMed ID: 15753225
    [No Abstract]   [Full Text] [Related]  

  • 32. [Glycoprotein IIb/IIIa platelet blockers in acute myocardial infarct treated with primary coronary angioplasty].
    Kala P; Poloczek M; Bocek O; Jerábek P; Neugebauer P; Kosová J; Semrád B
    Vnitr Lek; 2002 Aug; 48(8):736-41. PubMed ID: 12425204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ischemic coronary syndromes and SVG Interventions--do 2b/3a inhibitors miss the target?
    Topaz O
    Catheter Cardiovasc Interv; 2007 Apr; 69(5):630-1. PubMed ID: 17377986
    [No Abstract]   [Full Text] [Related]  

  • 34. [Theombolysis with GP IIb/IIIa-receptor blockader. Platelt aggregation inhibition: clear indications, new strategies].
    Internist (Berl); 1998 Dec; 39(12 Suppl Plattchena):1-4. PubMed ID: 10101692
    [No Abstract]   [Full Text] [Related]  

  • 35. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Usefulness of platelet glycoprotein IIb/IIIa inhibitors in coronary stenting for reconstruction of complex lesions: procedural and 30 day outcome.
    Galassi AR; Russo G; Nicosia A; Tamburino C; Foti R; Rodi G; Calvi V; Gulizia G; Distefano G; Moshiri S; Giuffrida G
    Cardiologia; 1999 Jul; 44(7):639-45. PubMed ID: 10476589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy).
    Rebeiz AG; Dery JP; Tsiatis AA; O'shea JC; Johnson BA; Hellkamp AS; Pieper KS; Gilchrist IC; Slater J; Muhlestein JB; Joseph D; Kitt MM; Tcheng JE;
    Am J Cardiol; 2004 Oct; 94(7):926-9. PubMed ID: 15464679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Local delivery of glycoprotein IIb/IIIa receptor inhibitors using drug eluting stents.
    Gershlick AH
    Semin Interv Cardiol; 1998; 3(3-4):185-90. PubMed ID: 10406691
    [No Abstract]   [Full Text] [Related]  

  • 39. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.
    ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
    Lancet; 2000 Dec; 356(9247):2037-44. PubMed ID: 11145489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
    Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE;
    Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.